Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benjamin Logan Lampson, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petrácková A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, Shupe S, Machado JH, Fardoun R, Kim AS, Brown JR. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia. J Clin Oncol. 2022 Oct 31; JCO2200269. PMID: 36315919.
    Citations:    Fields:    
  2. Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 10; 22(10):1391-1402. PMID: 34534514.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  3. Lampson BL, Brown JR. The Evolving Use of Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Hematol Oncol Clin North Am. 2021 08; 35(4):807-826. PMID: 34174987; PMCID: PMC8239250.
    Citations: 3     Fields:    Translation:Humans
  4. Vartanov AR, Lampson BL, Jacobsen ED, Alyea EP, Moslehi JJ, Brown JR. High-grade heart block associated with ibrutinib therapy. HeartRhythm Case Rep. 2021 Jun; 7(6):391-394. PMID: 34194987.
    Citations: 1     
  5. Koduri V, Duplaquet L, Lampson BL, Wang AC, Sabet AH, Ishoey M, Paulk J, Teng M, Harris IS, Endress JE, Liu X, Dasilva E, Paulo JA, Briggs KJ, Doench JG, Ott CJ, Zhang T, Donovan KA, Fischer ES, Gygi SP, Gray NS, Bradner J, Medin JA, Buhrlage SJ, Oser MG, Kaelin WG. Targeting oncoproteins with a positive selection assay for protein degraders. Sci Adv. 2021 02; 7(6). PMID: 33547076; PMCID: PMC7864573.
    Citations: 7     Fields:    Translation:HumansCells
  6. Lampson BL, Tyekucheva S, Crombie JL, Kim AI, Merryman RW, Lowney J, Montegaard J, Patterson V, Jacobson CA, Jacobsen ED, LaCasce AS, Arnason JE, Armand P, Fisher DC, Brown JR, Davids MS. Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL). Blood. 2019 Nov 13; 134(Supplement_1):32. PMID: 31723987.
  7. Sethi N, Kikuchi O, McFarland J, Zhang Y, Chung M, Kafker N, Islam M, Lampson B, Chakraborty A, Kaelin WG, Bass AJ. Mutant p53 induces a hypoxia transcriptional program in gastric and esophageal adenocarcinoma. JCI Insight. 2019 08 08; 4(15). PMID: 31391338.
    Citations: 12     Fields:    Translation:HumansAnimalsCells
  8. Lampson BL, Brown JR. For CLL cells, there's no place like home. Leuk Lymphoma. 2019 12; 60(14):3347-3349. PMID: 31373247.
    Citations:    Fields:    Translation:Humans
  9. Lampson BL, Kim HT, Davids MS, Abramson JS, Freedman AS, Jacobson CA, Armand PA, Joyce RM, Arnason JE, Rassenti LZ, Kipps TJ, Fein J, Fernandes SM, Hanna JR, Fisher DC, Brown JR. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019 04 09; 3(7):1167-1174. PMID: 30967392.
    Citations: 11     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  10. Lampson BL, Davids MS. A new triple threat to CLL. Blood. 2018 10 11; 132(15):1547-1548. PMID: 30309874.
    Citations:    Fields:    Translation:Humans
  11. Lampson BL, Brown JR. Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia? Expert Rev Hematol. 2018 03; 11(3):185-194. PMID: 29381098; PMCID: PMC6082118.
    Citations: 22     Fields:    Translation:HumansAnimals
  12. Lampson BL, Brown JR. PI3Kd-selective and PI3Ka/d-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2017 Nov; 26(11):1267-1279. PMID: 28945111; PMCID: PMC5747968.
    Citations: 24     Fields:    Translation:HumansAnimals
  13. Lampson BL, Yu L, Glynn RJ, Barrientos JC, Jacobsen ED, Banerji V, Jones JA, Walewska R, Savage KJ, Michaud GF, Moslehi JJ, Brown JR. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood. 2017 05 04; 129(18):2581-2584. PMID: 28223277; PMCID: PMC7219062.
    Citations: 63     Fields:    Translation:Humans
  14. Lampson BL, Davids MS. The Development and Current Use of BCL-2 Inhibitors for the Treatment of Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep. 2017 02; 12(1):11-19. PMID: 28116634; PMCID: PMC5862560.
    Citations: 17     Fields:    Translation:Humans
  15. Lampson BL, Gray SW, Cibas ES, Levy BD, Loscalzo J. CLINICAL PROBLEM-SOLVING. Tip of the Tongue. N Engl J Med. 2016 Sep 01; 375(9):880-6. PMID: 27579639.
    Citations: 1     Fields:    Translation:Humans
  16. Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Nov 15; 122(22):3456-3463. PMID: 27525836.
    Citations: 6     Fields:    
  17. Lampson BL, Kasar SN, Matos TR, Morgan EA, Rassenti L, Davids MS, Fisher DC, Freedman AS, Jacobson CA, Armand P, Abramson JS, Arnason JE, Kipps TJ, Fein J, Fernandes S, Hanna J, Ritz J, Kim HT, Brown JR. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203. PMID: 27247136; PMCID: PMC4946200.
    Citations: 123     Fields:    Translation:HumansCTClinical Trials
  18. Weyandt JD, Lampson BL, Tang S, Mastrodomenico M, Cardona DM, Counter CM. Wild-Type Hras Suppresses the Earliest Stages of Tumorigenesis in a Genetically Engineered Mouse Model of Pancreatic Cancer. PLoS One. 2015; 10(10):e0140253. PMID: 26452271.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  19. Pershing NL, Lampson BL, Belsky JA, Kaltenbrun E, MacAlpine DM, Counter CM. Rare codons capacitate Kras-driven de novo tumorigenesis. J Clin Invest. 2015 Jan; 125(1):222-33. PMID: 25437878; PMCID: PMC4382256.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  20. Lampson BL, Pershing NL, Prinz JA, Lacsina JR, Marzluff WF, Nicchitta CV, MacAlpine DM, Counter CM. Rare codons regulate KRas oncogenesis. Curr Biol. 2013 Jan 07; 23(1):70-5. PMID: 23246410.
    Citations: 78     Fields:    Translation:HumansCells
  21. Lampson BL, Kendall SD, Ancrile BB, Morrison MM, Shealy MJ, Barrientos KS, Crowe MS, Kashatus DF, White RR, Gurley SB, Cardona DM, Counter CM. Targeting eNOS in pancreatic cancer. Cancer Res. 2012 Sep 01; 72(17):4472-82. PMID: 22738914.
    Citations: 37     Fields:    Translation:HumansAnimalsCells
  22. Duncan CG, Killela PJ, Payne CA, Lampson B, Chen WC, Liu J, Solomon D, Waldman T, Towers AJ, Gregory SG, McDonald KL, McLendon RE, Bigner DD, Yan H. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget. 2010 Aug; 1(4):265-77. PMID: 21113414.
    Citations: 59     Fields:    Translation:HumansCells
  23. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM, Lampson B, Larson RA, Caligiuri MA, Heerema NA. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol. 2006 Jan 20; 24(3):437-43. PMID: 16344317.
    Citations: 75     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lampson's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (139)
Co-Authors (36)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.